Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty-five research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $813.57.

REGN has been the topic of a number of analyst reports. UBS Group lowered their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a report on Thursday, June 5th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Finally, Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target on the stock.

Regeneron Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:REGN opened at $545.00 on Monday. The firm has a market cap of $58.84 billion, a P/E ratio of 13.87, a P/E/G ratio of 2.00 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $1,211.20. The business has a fifty day simple moving average of $549.38 and a 200 day simple moving average of $624.74.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 earnings per share. Analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the last quarter. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Finally, Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.